Membranous nephropathy and cancer in the era of PLA 2 R testing
Journal of Onco-Nephrology · 2018
DOI: 10.1177/2399369318816333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Onco-Nephrology, 2018. Verfasst von Pascale Khairallah und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Membranous nephropathy has historically been associated with a higher risk of malignancy compared to the general population. Following a membranous nephropathy diagnosis, physicians screen patients for underlying cancers at the time of and up to several years following the diagnosis. The discovery of phospholipase A 2 receptor (PLA 2 R) as a major antigen in primary membranous nephropathy may be changing how we think about the association between membranous nephropathy and cancer. PLA 2 R was found to be present in 72% of cases of idiopathic membranous nephropathy with very few PLA 2 R patients having cancer. Following PLA 2 R discovery, thrombospondin type-1 domain-containing 7A (THSD7A) was discovered. This antigen, in contrast to PLA 2 R, may be more strongly associated with cancer. This review will evaluate the associations between these antigens and cancer, as well as propose an algorithm on cancer screening in the era of antibody testing.
Zitieren
APA
Khairallah, P., & Bomback, A. (2018). Membranous nephropathy and cancer in the era of PLA 2 R testing. Journal of Onco-Nephrology. https://doi.org/10.1177/2399369318816333
Vancouver
Khairallah P, Bomback A. Membranous nephropathy and cancer in the era of PLA 2 R testing. Journal of Onco-Nephrology. 2018. doi:10.1177/2399369318816333
BibTeX
@article{Khairallah2018,
author = {Khairallah, Pascale and Bomback, Andrew},
title = {Membranous nephropathy and cancer in the era of PLA 2 R testing},
journal = {Journal of Onco-Nephrology},
year = {2018},
doi = {10.1177/2399369318816333}
}
EUVIMED